携“减肥神针”递表,先为达生物想做国产司美格鲁肽

和讯
Sep 23

近期,医药领域的热度被“减重”这一话题带火了。以司美格鲁肽为代表的GLP-1产品正迅速成为明星产品。根据Insight数据库搜集的2025上半年全球药品销售额显示,司美格鲁肽以166.32亿美元超越默沙东的帕博利珠单抗实现登顶,首次打破了肿瘤药长期占据榜首的局面,更是与替尔泊肽开创了GLP-1类药物同时挤进市场前三的行业格局。来源:Insight数据库不久前,一家名为杭州先为达生物科技股份有限公司...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10